Sanofi (SNY) announces that it has entered into an agreement with Janssen Pharmaceuticals, a Johnson & Johnson (JNJ) company, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli developed by Janssen, currently in Phase 3. “The agreement brings together Janssen’s robust science behind this potential first-in-class product and Sanofi’s worldwide manufacturing footprint and recognized world-class expertise in launching innovative vaccines,” Sanofi stated. Under the terms of the agreement, both parties will co-fund current and future research and development costs. Sanofi will pay USD 175M upfront to Janssen, followed by development and commercial milestones. There will be a profit-share arrangement in the U.S., EU4 and the UK. In the rest of the world, Janssen will receive tiered royalties and sales milestones. Closing is subject to customary regulatory clearance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNY:
- Eli Lilly’s lebrikizumab CRL impact ‘likely limited,’ says Morgan Stanley
- Syneos Health appoints Terttu Haring as president, clinical sites & patients
- Regeneron, Sanofi announce FDA acceptance for Priority Review of Dupixent sBLA
- Sanofi price target raised to EUR 108 from EUR 100 at Morgan Stanley
- Sanofi says once-weekly Altuviiio approved in Japan